La Jolla Pharmaceutical Co

La Jolla Pharmaceutical — Investor Presentation (February 2013)

51 slides from La Jolla Pharmaceutical's investor presentation, Feb 4, 2013

  1. Slide 1: Pioneering Innovative Therapies to Treat Chronic Organ Failure and Cancer

    Pioneering Innovative Therapies to Treat Chronic Organ Failure and Cancer George F. Tidmarsh, MD, PhDChief Executive OfficerJanuary 2013

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements These slides contain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward looking terminology such as "anticipate", "believe", "continue", "could", "estimate", "exp

  3. Slide 3: An Introduction to La Jolla

    An Introduction to La Jolla (LJPC) The Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 3

  4. Slide 4: Mission

    Mission La Jolla Pharmaceutical: Reducing Human SufferingNovel Therapies Harnessing the Immune SystemTo Treat Life-Threatening Diseases 4

  5. Slide 5: Corporate Highlights

    Corporate Highlights 5 Technology Immune therapy platform targeting Galectin-3, an innate protein with a demonstrated role in organ failure and cancer via immune regulationClear path to proof-of-conceptPipelineProduct candidate: GCS-100 - Leading, clinical stage galectin-3 antagonistMay prevent or r

  6. Slide 6: Robust Product Pipeline

    ~~ Robust Product Pipeline 665100 ChenckKieney 000 > Kidney Disease End Stage Renal Disease turc-so1 Ent Sie Rea ee * a> scsi SHC VP > Liver — Disease Lipc21 Hepat boss «= PD> Cancer » 610 ig TY > Lipc.301 Sold Tuo PR > , ou Cancer

  7. Slide 7: The Technology of La Jolla

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 7

  8. Slide 8: Galectins and Galectin-3

    Galectins and Galectin-3 8 Galectins are proteins that can bind to specific sugars on other proteins (receptors) to modulate cellular function and communication. Galectin 3 is unique in that it can self-associate allowing it to bind to several receptors at once. Gal-3 is normally present at low conc

  9. Slide 9: GCS-100: The Leading Galectin-3 Antagonist

    GCS-100: The Leading Galectin-3 Antagonist GCS-100 is a well-characterized, complex sugar derived from pectinGCS-100 binds to and neutralizes galectin-3. Binding activity is localized to the galactose containing side-branchesPatented manufacturing process required for biologic activity; unmodified p

  10. Slide 10: GCS-100 and Organ Failure

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 10

  11. Slide 11: Galectin-3 and Organ Failure: Kidney, Heart, Liver

    Galectin-3 and Organ Failure Kidney, Heart, Liver Mice lacking galectin-3 develop significantly less kidney fibrosis and failure after damage compared to normal mice1,2 Mice lacking galectin-3 develop significantly less liver fibrosis when exposed to toxin3Galectin-3 serum assay is FDA approved to i

  12. Slide 12: Galectin-3 in the General Population

    Galectin-3 in the General Population 12

  13. Slide 13: Galectin-3 in the General Population

    Galectin-3 in the General Population High galectin-3 is independently associated with lower survival in the general population 13 Journal of Internal Medicine, 2012, 272; 55-64.

  14. Slide 14: Galectin-3: Promotes Organ Failure via Scar Formation

    Galectin-3: Promotes Organ Failure via Scar Formation Mice genetically altered to lack galectin-3 produce much less scar tissue in the kidney after injury. Normal (wild-type, WT) mice or galectin-3 knockout mice were either left alone (-) or surgically injured by obstructing the outflow of urine fro

  15. Slide 15: Chronic Kidney Disease Market

    Chronic Kidney Disease Market 49 million Americans suffer with CKD1$7.1 billion spent on CKD therapeutics in 20102Market growth of 6.4% CAGR over the next 5 years2 15 The United States Renal Data System, 2012 Annual Data Report Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Mark

  16. Slide 16: Liver Disease Market

    Liver Disease Market 16 The National Institute of Diabetes and Digestive and Kidney Diseases Liver Disease Treatments: The Global Market, January 1, 2012 BCC Research 17.5 million Americans suffer with CLD1$12.4 billion spent on CLD therapeutics in 20102CLD market growth of 3.3% CAGR expected until

  17. Slide 17: GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model

    GCS-100 is Effective in Liver Fibrosis: Stelic NASH Model 17 Boehringer Ingelhiem GmbH & Co. KGGalectin Therapeutics Effect of GCS-100 in liver fibrosis was studied by an independent, contract research groupThe 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD 20

  18. Slide 18: Stelic NASH Model

    Stelic NASH Model 18 Treatment Control GCS-100 1 mg/kg GCS-100 25 mg/kg Endpoints Pathology Serum Chemistry NAFLD Score Fibrosis

  19. Slide 19: GCS-100 Treatment Reduced Liver Fibrosis

    GCS-100 Treatment Reduced Liver Fibrosis 19 Each circle represents data from one mouse.

  20. Slide 20: GCS-100 Treatment Reduced Liver Fibrosis

    GCS-100 Treatment Reduced Liver Fibrosis 20

  21. Slide 21: GCS-100 Treatment Reduced Disease Activity

    GCS-100 Treatment Reduced Disease Activity 21

  22. Slide 22: GCS-100 Improved Gross Pathology

    GCS-100 Improved Gross Pathology 22 Vehicle GCS-100

  23. Slide 23: GCS-100 Improved Microscopy Pathology

    GCS-100 Improved Microscopy Pathology 23

  24. Slide 24: GCS-100 Reduced Liver Damage: Liver Enzymes

    GCS-100 Reduced Liver Damage: Liver Enzymes 24 Normal Value p < 0.05

  25. Slide 25: GCS-100 Effect of NASH: Summary

    GCS-100 Effect of NASH: Summary Significant reduction in fibrosis as measured by Sirius Red stainingSignificant reduction in NAFLD scoreSignificant reduction in plasma ALTNo change in:Body weightSerum glucoseLiver weightLiver hydroxyprolineCollagen mRNA 25

  26. Slide 26: GCS-100 and Cancer

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 26

  27. Slide 27: Galectin-3 and Cancer

    Galectin-3 and Cancer Over-expression of galectin-3 correlates with aggressiveness and relapse in multiple human cancers1,2 Galectin-3 expression increases the spread of cancer in animal models1,2 Galectin-3 suppresses anti-tumor T-cell activity3Lung tumor formation is reduced in galectin-3 -/- vs.

  28. Slide 28: Galectin-3 Expression Correlates with Reduced Patient Survival

    Galectin-3 Expression Correlates with Reduced Patient Survival Survival curve of colorectal cancer patients with positive and negative galectin-3 expression. The prognosis of patients was significantly worse in patients with galectin-3-positive expression (purple line) than in galectin-3- negative p

  29. Slide 29: Galectin-3 Suppresses T-Cell Activation

    Galectin-3 Suppresses T-Cell Activation 29 Source: Pierre van der Bruggen, Ludwig Institute for Cancer Research Galectin-3 Galectin-3 binding to cell surface glycoproteins blocksco-receptor association and cell signal transmission

  30. Slide 30: GCS-100 Reverses Galectin-3 T-Cell Suppression

    GCS-100 Reverses Galectin-3 T-Cell Suppression 30 Source: Pierre van der Bruggen, Ludwig Institute for Cancer Research Galectin-3 GCS-100

  31. Slide 31: GCS-100 Reverses Galectin-3 T-Cell Suppression

    GCS-100 Reverses Galectin-3 T-Cell Suppression T-cells were collected from 4 ovarian cancer patients and tested for their ability to kill the tumor (T-cell Activity). Untreated cells have little activity. After treating the T-cells with either an antibody to galectin-3 (purple) or with GCS-100 (blue

  32. Slide 32: GCS-100 Improves Melanoma Cancer Vaccine

    GCS-100 Improves Melanoma Cancer Vaccine Animals treated with GCS-100 in addition to a vaccine against the tumor live much longer than untreated animals or animals treated with vaccination or GCS-100 alone 32 Source: Dermotte et al. A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and

  33. Slide 33: Cancer Immunotherapy Market

    Cancer Immunotherapy Market $1.7 billion spent on cancer immunotherapy in 2010121% CAGR for cancer vaccine market from 2010 to 20171Current ProductsYervoyTM (BMS)ProvengeTM (Dendreon) 33 GBI Research, "Emerging Cancer Vaccines Market to 2017 - Novel, First-In-Class Vaccines in Phase II and Phase III

  34. Slide 34: GCS-100's History in the Clinic

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 34

  35. Slide 35: GCS-100 Clinical Summary

    GCS-100 Clinical Summary 150 patients dosed in 9 Phase 1 and Phase 2 clinical trialsSignificant clinical activity in multiple cancers, including chronic lymphocytic leukemia (CLL), multiple myeloma (MM), renal cell carcinomaPharmacokinetic parameters establishedSingle- and multiple-dose administrati

  36. Slide 36: GCS-100 Side Effects Consistent with Immune Modulation

    GCS-100 Side Effects Consistent with Immune Modulation Doses up to 160 mg/m2 well tolerated in 24-patient solid tumor study Minimal hematological toxicityOnly drug-related grade 3 AEs = rash (8%), arthralgia (8%) and myalgia (4%), all consistent with immune effectsDose-Limiting ToxicityGrade 3 rashR

  37. Slide 37: Phase 2a Single-Agent CLL Study: Design

    Phase 2a Single-Agent CLL Study: Design Enrolled 24 patients with one or two prior therapiesMedian age 67 years old; 15 patients > 67 years, 4 > 80 yearsPrior therapies include multi-drug chemotherapyDosing regimen160 mg/m2 i.v. daily for 5 days on 21-day cycleRegimen from Phase 1 solid tumor studyS

  38. Slide 38: Phase 2a Single-Agent CLL Study: Results

    Phase 2a Single-Agent CLL Study: Results GCS-100 was well tolerated Minimal hematologic toxicity1 patient discontinued due to rashNo drug-related SAEsIn vivo evidence of expected biologic effect16/24 patients (25%) achieved partial remission and 12/24 (50%) achieved stable disease, (75% disease cont

  39. Slide 39: GCS-100 Clinical Summary

    GCS-100 Clinical Summary Clinical activity in multiple cancer typesWell tolerated and has low toxicity based on >140 patients treatedBroad-based synergy in vitro with both chemotherapy and other targeted agentsSingle agent activity observedRash, arthralgias, myalgias and increase in neutrophil count

  40. Slide 40: Phase 1/2 Clinical Trial

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 40

  41. Slide 41: Next Steps: Clinical Trial Rationale

    Next Steps: Clinical Trial Rational Galectin-3 is increased and the level correlates to overall survival in end-stage renal disease patientsGalectin-3 knockout mice develop less kidney scar after injuryPatients with chronic kidney disease have no existing therapeutic options outside of renal transpl

  42. Slide 42: CKD Phase 1/2 Trial Part A

    CKD Phase 1/2 Trial 42 Part A Day-21 Day-8 Day0 Day7 Screening Visit 1 Screening Visit 2 Each cohort n=3 patients(up to 6 cohorts) GCS-1001.5-20 mg/m2 IV D-0 D - -21,-8 Data collected on:Blood gal-3, Cytokine, Serum chemistry, Quantitative urine analysis, and eGFR rate Data Collection Point Dosing P

  43. Slide 43: CKD Phase 1/2 Trial Part B

    CKD Phase 1/2 Trial 43 Part B Day0 Day7 Day49 Day56 D - 0,7 n=18 patients GCS-1001.5-20 mg/m2 IV D-0 D-7 D-21 D-28 D-35 D-42 D-49 Data collected on:Blood gal-3, Cytokine, Serum chemistry, Quantitative urine analysis, and eGFR rate Data Collection Point Dosing Point Key Day14 D-14 Day28 Day42 Day35 D

  44. Slide 44: Phase 1/2 Study in Chronic Kidney Disease

    Phase 1/2 Study in Chronic Kidney Disease First Patient Dosed with GCS-100 4 leading sites in the USRapid enrollment anticipatedAccelerated path to Phase 2 DataSingle-dose, dose-escalation Phase 1 (Part A)Endpoints:Maximum tolerated doseSafety Multiple dose Phase 2 (Part B)Endpoints:Kidney functionS

  45. Slide 45: Patents and Financials

    An Introduction to La JollaThe Technology of La JollaGCS-100 and Organ FailureGCS-100 and CancerGCS-100's History in the ClinicPhase 1/2 Clinical TrialPatents and Financials 45

  46. Slide 46: Intellectual Property Position

    Title Status Expiration Modified Pectins, Compositions and Methods Related Thereto Issued US 8,128,966 2028 Modified Pectins, Compositions and Methods Related Thereto Issued US 8,187,642 2025 Modified Pectins, Compositions and Methods Related Thereto Pending US 13/588,932 2025 Modified Pectins, Comp

  47. Slide 47: Key Financial Information

    Key Financial Information As of Q3 2012 Cash was $3,363,000Will take us through 2013Additional $10,646,000 in secured financingWill take us through 20152013 projected R&D spending to be 60% of total cash burn319% increase in R&D spending from 2012 47

  48. Slide 48: Stock Information

    Stock Information Stock Information 48

  49. Slide 49: Robust Product Pipeline

    ~~ Robust Product Pipeline 6c8-100 Chenickiney se > Kidney Disease End Stage Renal Disease turc-so1 Ent Sie Rea ee * a> scsi SHC VP > Liver — Disease Lipc21 Hepat boss «= PD> ecs-100 A TR) > Immunemodton Lupc.s0t a Cancer « ou

  50. Slide 50: Corporate Highlights

    Corporate Highlights Technology Immune therapy platform targeting, Galectin-3, an emerging key with a demonstrated role in organ failure and cancer via immune regulationClear path to proof-of-conceptStrong IP position with broad, issued patents PipelineProduct candidate: GCS-100 - Leading, clinical

  51. Slide 51: Thank You

    / @La Jolla Pharmaceutical Thank You

LA Jolla Pharmaceutical — Investor Presentation (February 2013) on 6ix